Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Cancer Type/Condition:  Breast cancer, female
Trial Type:  Treatment
Treatment/Intervention:  neoadjuvant therapy
Results 1-25 of 28 for your search:
Start Over
Fulvestrant and/or Anastrozole in Treating Postmenopausal Patients with Stage II-III Breast Cancer Undergoing Surgery
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: A011106, NCI-2013-01340, NCT01953588
Docetaxel or Doxorubicin Hydrochloride and Cyclophosphamide Before Surgery in Treating Patients With Breast Cancer
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: H-16039, NCI-2012-00652, NCT00206518
Anastrozole With or Without Fulvestrant in Treating Postmenopausal Patients With Hormone Receptor Positive Breast Cancer
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: H-20431, NCI-2012-00645, NCT00570323
Laboratory Treated T Cells after Chemotherapy in Treating Patients with HER2-Negative Stage II-III Breast Cancer That Can Be Removed by Surgery
Status: Temporarily closed
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 2010-056, NCI-2011-02634, 1005008403, CDR0000675211, NCT01658969, WSU-2010-056, NCT01147016
Carboplatin and Paclitaxel Albumin-Stabilized Nanoparticle Formulation before Surgery in Treating Patients with Locally Advanced or Inflammatory Triple Negative Breast Cancer
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 19 and over
Trial IDs: 11174, NCI-2012-00025, 103352, 109696, 110312, 118191, NCT01525966
Cisplatin or Doxorubicin Hydrochloride and Cyclophosphamide before Surgery in Treating Patients with Newly Diagnosed Breast Cancer and BRCA Mutations
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 12-258, NCI-2012-02217, TBCRC031, NCT01670500
PD 0332991 and Anastrozole for Stage 2 or 3 Estrogen Receptor Positive and HER2 Negative Breast Cancer
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 201301106, NCI-2012-02202, NCT01723774
Paclitaxel and Cyclophosphamide with or without Trastuzumab before Surgery in Treating Patients with Previously Untreated Stage I-III Breast Cancer
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 19 and over
Trial IDs: 264-12, NCI-2012-01372, NCT01750073
Study of Letrozole With or Without BYL719 or Buparlisib, for the Neoadjuvant Treatment of Postmenopausal Women
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CBYL719A2201, NCI-2014-00149, NCT01923168
Cisplatin or Paclitaxel before Surgery in Treating Patients with Triple Negative Stage I-III Breast Cancer
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 13-383, NCI-2014-00955, 030, TBCRC 030, NCT01982448
Neoadjuvant Treatment of Triple Negative Breast Cancer Patients with Docetaxel and Carboplatin to Assess Anti-tumor Activity
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 201404107, NCI-2014-01037, NCT02124902
A Study of Neoadjuvant Letrozole + GDC-0032 Versus Letrozole + Placebo in Post-Menopausal Women With Breast Cancer (LORELEI)
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: GO28888, NCI-2014-02653, 2013-000568-28, NCT02273973
Talazoparib before Standard Therapy in Treating Patients with Invasive, BRCA-Mutated Breast Cancer
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 2014-0045, NCI-2015-00335, NCT02282345
A Phase II Randomized Study Evaluating the Biological and Clinical Effects of the Combination of Palbociclib With Letrozole as Neoadjuvant Therapy in Post-Menopausal Women With Estrogen-Receptor Positive Primary Breast Cancer
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: NSABP FB-11, NCI-2015-00998, WI180455, NCT02296801
A Study of Ipatasertib (GDC-0068) in Combination With Paclitaxel as Neoadjuvant Treatment for Patients With Early Stage Triple Negative Breast Cancer
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: GO29505, NCI-2015-01653, 2014-003029-16, NCT02301988
Pegylated Liposomal Doxorubicin Hydrochloride and Carboplatin Followed by Surgery and Paclitaxel in Treating Patients with Triple Negative Stage II-III Breast Cancer
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 041401, NCI-2014-02029, NCT02315196
Carboplatin and Docetaxel or Carboplatin and Paclitaxel Followed by Doxorubicin Hydrochloride and Cyclophosphamide in Treating Patients with Stage I-III Triple-Negative Breast Cancer
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 to 70
Trial IDs: 2015-IIT-Neoadjuvant-BRST-TNBC, NCI-2015-01416, 2014-BRST-TNBC-LQT, STUDY00002467, NCT02413320
Carboplatin and Paclitaxel with Pertuzumab and Trastuzumab or Bevacizumab in Treating Patients with Breast Cancer
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: UCI 14-67, NCI-2015-02066, NCT02436993
Enzalutamide and Paclitaxel before Surgery in Treating Patients with Stage I-III Androgen Receptor-Positive Triple-Negative Breast Cancer
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 2015-0488, NCI-2016-00367, NCT02689427
Letrozole with or without Ribociclib before Surgery in Treating Women with Stage II-III Estrogen Receptor-Positive, HER2-Negative Breast Cancer
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CLEE011XUS10T, NCI-2016-00423, STUDY00002972, NCT02712723
Veliparib and Radiation Therapy before Surgery in Treating Patients with Stage IIB-IV Breast Cancer with Incomplete Response to Chemotherapy
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: J11155, NCI-2012-02760, CIR00006912, NA_00048362, NCT01618357
Mammaglobin-A DNA Vaccine in Treating Patients with Newly Diagnosed Breast Cancer Undergoing Endocrine Therapy before Surgery
Status: Active
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 201407100, NCI-2014-01457, 14-x092, NCT02204098
Letrozole Before Surgery in Treating Post-Menopausal Patients With Stage I-III Hormone-Sensitive Breast Cancer That Can Be Removed By Surgery
Status: Active
Phase: No phase specified
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: VICC BRE 0776, NCI-2010-02165, BRE0776, VU-VICC-BRE-0776, VU-VICC-IRB-080064, NCT00651976
Chemotherapy before Surgery and Tissue Sample Collection in Patients with Stage IIA-IIIC Breast Cancer
Status: Active
Phase: No phase specified
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 13-02-079, NCI-2013-01194, NCT01897441
Metformin Hydrochloride and Atorvastatin Calcium in Treating Patients with Newly Diagnosed Breast Cancer That Can Be Removed by Surgery
Status: Active
Phase: No phase specified
Type: Biomarker/Laboratory analysis, Treatment
Age: 21 and over
Trial IDs: IRB-AAAM2306, NCI-2014-01506, AAAM2306, Y1M00, NCT01980823
Start Over